Skip to content
Company Analysis

InMed Pharmaceuticals Inc. INM

A comprehensive view of key metrics, scores, and financial health for InMed Pharmaceuticals Inc.

Overview of InMed Pharmaceuticals Inc.

INM NCM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap
InMed Pharmaceuticals Inc. (INM), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $1.59, about 0.0% overvalued vs fair value, -20.5% 1Y return, ranked 1018/1145 in sector.
Metrics ROE -173.1%
USD 1.59
0.00%
(Delayed)
• Vol 90d: 55.8%
52-Week Range
Market Cap
$10.56M
Enterprise Value
$8.37M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Weak
Valuation
Fair
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Weak
Valuation
Fair
Completeness: 82%
Confidence: 85%
Updated: Oct 24
Top Beats

Quick Facts

Website https://www.inmedpharma.com
HQ Vancouver, BC
Employees 13
Fiscal year Jun 30

Next Events

Earnings Nov 5 Estimated

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$0
Gross Profit
$1.7M
55%%
R&D Expense
$3.0M
7.3%%
Operating Income (EBIT)
-$11.4M
-36.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating InMed Pharmaceuticals Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
19
/100
Weak
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.97), with margins expanding over time.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 18.5th percentile with high volatility suggests weak pricing power or commoditized products.
  • ROIC Below WACC or Peers ROIC at 2.4th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
9
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 77% Coverage
Trade-Off Triangle Visualization A ternary plot showing INM's balance between Growth (30.9%), Profitability (12.4%), and Safety (56.7%). Growth 31% Safety 57% Profitability 12%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

26th percentile vs peers
27
Key Signals
EPS Growth YoY 63.9% 60p Rev Growth YoY -1.00 4p
Strengths
  • D/E Ratio in top 20% of peers (0.0%, 85th percentile)
  • Quick Ratio in top 20% of peers (6.47, 93th percentile)
  • Strong liquidity position vs peers
  • Conservative leverage compared to industry peers
Risks
  • Rev Growth YoY in bottom 20% of peers (-1.00)

Profitability

10th percentile vs peers
11
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

48th percentile vs peers
49
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for InMed Pharmaceuticals Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000